ORLANDO, Fla., March 13, 2008 (PRIME NEWSWIRE) -- RedChip Visibility, a division of RedChip Companies, Inc., today announced it has issued a third quarter fiscal 2008 research report update for GeoPharma, Inc. (Nasdaq:GORX), a company specializing in the manufacture and distribution of over-the-counter, nutritional, generic drug and functional food products.
Andre Garnet, MBA, RedChip Research Analyst, reported:
"The Company's growth strategy in the generic drugs area is to capitalize on its product selection and manufacturing expertise to develop high-margin generic or novel drugs for niche markets with high barriers to entry. The Company is poised for rapid revenue and earnings growth as it expands operations and prepares to launch over a dozen new generic drugs within two years."
"The Company also confirmed during a conference call on February 14, 2008, that it is preparing to meet with the FDA for discussions about beginning clinical trials of its new diagnostic test intended for the early detection of ovarian cancer. We view this as a major development given the large potential market for such a test. Management stated that it plans to develop and commercialize this product in-house as opposed to out-licensing it, which means that the Company intends to take full advantage of this business opportunity," Garnet continued in the report.
"We leave unchanged our Speculative Buy recommendation and our price target of $8.00 for GORX," he concluded.
To receive a complimentary copy of the RedChip Visibility Third Quarter Research Report for GeoPharma, Inc., please visit:
http://www.redchip.com/visibility/about.asp?page=vreport&reportid=92&from=03102008news
To learn more about GeoPharma, visit http://www.visualwebcaster.com/REDCHIP/45650/event.html to view the company's webcast presentation, delivered at RedChip's Small-Cap Investor conference in Scottsdale, Arizona, Feb. 7, 2008.
About RedChip Companies, Inc.
RedChip Companies is an international small-cap research and financial public relations firm with offices in Beijing and Orlando and affiliates in New York and San Diego. Dedicated to "Discovering Tomorrow's Blue Chips Today,"(tm) RedChip delivers concrete, measurable results for its clients through its extensive international market expertise as well as its comprehensive platform of products and services, which include RedChip Research(tm), Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences held throughout the United States, RedChip TV(tm) and RedChip Radio(tm). To learn more about RedChip's products and services please visit: http://www.redchip.com/visibility/services.asp
The RedChip Companies Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=2761
DISCLOSURE:
The analyst(s) contributing to this report do not hold any shares of GORX. Additionally, the analyst(s) contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. RedChip certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and is not purported to be complete. As such, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed therein are subject to change.GeoPharma, Inc. paid RedChip Visibility $49,000 for 12 months of the RedChip Visibility Research Program services, which includes this equity research report.
To the fullest extent permissible under applicable law, RedChip Companies, Inc., will not be liable to you or anyone else for the quality, accuracy, completeness, reliability or timeliness of this information. To the fullest extent permitted by law, RedChip Companies, Inc., will not be liable to you or anyone else under any tort, contract, negligence, strict negligence, strict liability, products liability or other theory with respect to this presentation of information.